Cascade Analysis for Women Presenting With Breast Concerns to a Zonal Hospital in Mwanza, Tanzania.

Tara M Friebel-Klingner, Emma Joo, Matogoro Kirahi, Lydia E Pace, Elizabeth A Platz, Nestory Masalu, Leonard Washington, Anne F Rositch
Author Information
  1. Tara M Friebel-Klingner: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. ORCID
  2. Emma Joo: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
  3. Matogoro Kirahi: Bugando Medical Centre, Mwanza, Tanzania.
  4. Lydia E Pace: Brigham and Women's Hospital, Boston, MA. ORCID
  5. Elizabeth A Platz: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. ORCID
  6. Nestory Masalu: Bugando Medical Centre, Mwanza, Tanzania. ORCID
  7. Leonard Washington: Bugando Medical Centre, Mwanza, Tanzania.
  8. Anne F Rositch: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. ORCID

Abstract

PURPOSE: In Tanzania, high breast cancer mortality can be attributed to delays in diagnosis and treatment initiation. We adapted the cascade analysis method to depict sequential steps along the breast cancer care pathway in a tertiary hospital in Mwanza, to identify where correction of loss to attrition would have the biggest impact on improving outcomes.
METHODS: This prospective cohort included adult women presenting with breast concerns between February 2020 and January 2022. Five cascade steps beginning with patients' initial clinical breast assessment (CBA) through cancer treatment were identified: (1) CBA, (2) ordering diagnostic test(s), (3) completion of diagnostic test(s), (4) receipt of final diagnosis, and (5) initiating cancer treatment.
RESULTS: Overall, 721 eligible women with a median age of 42.8 years (IQR, 32.5-55.0) were included. Median time from presentation to treatment initiation was 35 days (IQR, 20-63). For step 1, 39.1% (n = 282) of patients were diagnosed with a benign concern and removed from the cascade. Completion rates for steps 2-4 were 95.0%, 90.2%, and 91.0, respectively. There were 156 (45.6%) patients diagnosed with breast cancer, and for step 5, 71.2% of patients initiated cancer treatment. In steps 2, 3, 4, and 5, there was a loss of 22, 41, 34, and 45 patients, respectively. If loss was eliminated at steps 2, 3, 4, or 5, an additional 6, 12, 11, or 45 patients, respectively, would have completed the pathway.
CONCLUSION: Initiating cancer treatment was identified as the step with the biggest loss and, if remedied, would have the biggest impact on improving breast cancer outcomes at Bugando Medical Centre. These results will inform future programs focused on reducing overall loss in the system and supporting patients with breast cancer.

References

  1. JCO Glob Oncol. 2020 Sep;6:1419-1421 [PMID: 32970486]
  2. Int J Gynaecol Obstet. 2017 Jul;138(1):53-61 [PMID: 28391628]
  3. BMC Cancer. 2021 May 10;21(1):527 [PMID: 33971839]
  4. JCO Glob Oncol. 2021 Mar;7:368-377 [PMID: 33689484]
  5. Lancet. 2003 May 17;361(9370):1723-9 [PMID: 12767751]
  6. J Glob Oncol. 2018 Sep;4:1-8 [PMID: 30241225]
  7. J Natl Compr Canc Netw. 2021 May 01;19(5):484-493 [PMID: 34794122]
  8. Cancer. 2020 May 15;126 Suppl 10:2394-2404 [PMID: 32348574]
  9. PLoS One. 2017 Feb 7;12(2):e0171284 [PMID: 28170413]
  10. Cancer. 2020 May 15;126 Suppl 10:2379-2393 [PMID: 32348566]
  11. BMJ Glob Health. 2020 Nov;5(11): [PMID: 33173011]
  12. Oncologist. 2021 Feb;26(2):157-164 [PMID: 33210345]
  13. Breast J. 2006 Jan-Feb;12 Suppl 1:S3-15 [PMID: 16430397]
  14. PLoS One. 2014 Aug 13;9(8):e104961 [PMID: 25119665]
  15. Lancet Oncol. 2014 Dec;15(13):1421-1423 [PMID: 25456360]
  16. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  17. Gates Open Res. 2019 Jun 7;3:1488 [PMID: 31942536]
  18. Cancer. 2020 May 15;126 Suppl 10:2339-2352 [PMID: 32348573]
  19. J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3:S322-S331 [PMID: 31764270]
  20. Lancet. 2018 Mar 17;391(10125):1023-1075 [PMID: 29395269]
  21. Oncologist. 2019 Sep;24(9):1195-1200 [PMID: 30498134]
  22. PLoS One. 2021 Sep 13;16(9):e0257163 [PMID: 34516552]
  23. BMC Public Health. 2020 Jun 15;20(1):930 [PMID: 32539723]
  24. Implement Sci Commun. 2020 Feb 25;1:24 [PMID: 32885183]
  25. Lancet Oncol. 2016 Feb;17(2):146-148 [PMID: 26868339]
  26. Oncologist. 2021 Dec;26(12):e2200-e2208 [PMID: 34390287]

Grants

  1. T32 CA009314/NCI NIH HHS

MeSH Term

Adult
Humans
Female
Middle Aged
Tanzania
Prospective Studies
Breast Neoplasms
Cross-Sectional Studies
Hospitals

Word Cloud

Created with Highcharts 10.0.0cancerbreasttreatmentpatientsstepsloss5cascadebiggest234steprespectively45TanzaniadiagnosisinitiationpathwayMwanzaimpactimprovingoutcomesincludedwomenCBA1diagnostictestsIQR0diagnosed2%PURPOSE:highmortalitycanattributeddelaysadaptedanalysismethoddepictsequentialalongcaretertiaryhospitalidentifycorrectionattritionMETHODS:prospectivecohortadultpresentingconcernsFebruary2020January2022Fivebeginningpatients'initialclinicalassessmentidentified:orderingcompletionreceiptfinalinitiatingRESULTS:Overall721eligiblemedianage428years325-55Mediantimepresentation35days20-63391%n=282benignconcernremovedCompletionrates2-4950%90911566%71initiated224134eliminatedadditional61211completedCONCLUSION:InitiatingidentifiedremediedBugandoMedicalCentreresultswillinformfutureprogramsfocusedreducingoverallsystemsupportingCascadeAnalysisWomenPresentingBreastConcernsZonalHospital

Similar Articles

Cited By